93
Participants
Start Date
September 1, 2021
Primary Completion Date
June 1, 2023
Study Completion Date
November 10, 2023
Oxiris
Through a previously established and standardized management protocol, the treating team will prescribe renal replacement therapy by hemodiafiltration (CVVHDF) in the PrismaFlex device, at a dose of 25 mL / Kg of PrismaSate dialysis solutio and the removal filter oXiris® cytokines (Baxter) vs. the standard filter.
Clinica CES, Medellín
Lead Sponsor
Baxter Healthcare Corporation
INDUSTRY
Clinica CES
NETWORK